HCW BIOLOGICS INC (HCWB) Stock News

NASDAQ:HCWB - Nasdaq - US40423R2040 - Common Stock - Currency: USD

4.18 +0.09 (+2.2%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

HCWB Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: The Motley Fool

Hcw Biologics Revenue Plunges 98 Percent

24 days ago - By: Benzinga - Mentions: AHG ONCO HCTI EKSO ...

12 Health Care Stocks Moving In Friday's After-Market Session

a month ago - By: Benzinga - Mentions: CYCC APM YCBD CLNN ...

12 Health Care Stocks Moving In Friday's After-Market Session

2 months ago - By: HCW Biologics Inc.

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

2 months ago - By: HCW Biologics Inc.

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

3 months ago - By: HCW Biologics Inc.

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

3 months ago - By: HCW Biologics Inc.

HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

3 months ago - By: HCW Biologics Inc.

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

3 months ago - By: HCW Biologics Inc.

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

5 months ago - By: HCW Biologics, Inc

HCW Biologics Announces 1-for-40 Reverse Stock Split

5 months ago - By: HCW Biologics, Inc

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

6 months ago - By: HCW Biologics, Inc

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

7 months ago - By: HCW Biologics, Inc

HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

7 months ago - By: HCW Biologics, Inc

HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025